When should a metallo‑β‑lactamase (MBL)‑producing Enterobacter cloacae infection be suspected?

When to Suspect MBL-Producing Enterobacter cloacae

Suspect metallo-β-lactamase (MBL) production in Enterobacter cloacae when you encounter carbapenem resistance or reduced carbapenem susceptibility (even if MIC appears "susceptible" by older breakpoints), particularly in patients with prior carbapenem exposure, recent hospitalization, or healthcare-associated infections.

Key Clinical Triggers for Suspicion

Microbiological Red Flags

• Carbapenem MIC ≥2 μg/mL for imipenem/meropenem - Even isolates with MICs of 2 μg/mL (previously considered "susceptible" by old CLSI breakpoints) can harbor MBL genes and lead to treatment failure 1
• Resistance to ceftazidime-avibactam - This strongly suggests MBL production, as avibactam does not inhibit metallo-β-lactamases 2
• Paradoxical susceptibility pattern - Apparent susceptibility to carbapenems on routine testing but resistance to most other β-lactams should raise suspicion 3

High-Risk Patient Populations

The following clinical scenarios significantly increase MBL likelihood:

• Recent hospitalization (P = 0.006 for association with MBL-producers) 3
• Prior carbapenem exposure - Nearly 60% of MBL-producing Enterobacteriaceae infections occur in carbapenem-exposed patients 4
• Cirrhosis (P = 0.03) 3
• Critical care unit admission - Two-thirds of MBL infections occur in ICU settings 4, 5
• Prior colonization with carbapenem-resistant organisms - Most infected patients were previously colonized 4

Clinical Course Indicators

• Relapsing infection (P < 0.001) - MBL-producing E. cloacae infections have significantly higher relapse rates 3
• Prolonged antibiotic therapy requirement (P = 0.01) 3
• Treatment failure on carbapenem therapy - Approximately 30% of MBL infections occur in patients already receiving carbapenems, representing carbapenem treatment failure 4

Diagnostic Approach

Immediate Laboratory Actions

When MBL is suspected, request carbapenemase detection testing immediately 6:

Preferred methods (in order):

1. Genotypic testing - RT-PCR or molecular assays (98% sensitivity, 100% specificity, <3 hours turnaround) 6
2. Phenotypic testing if molecular unavailable:
   • Combined disc test (CDT) with EDTA: 100% sensitivity for MBL-only producers, 96.8% for co-producers 6
   • Modified carbapenem inactivation method with EDTA (eCIM): 95% concordance with PCR 6
   • Carba NP test: 95.9% sensitivity, 100% specificity 6

Critical Pitfall to Avoid

Do not rely solely on automated susceptibility systems or older CLSI breakpoints - Many clinical laboratories still use pre-2010 carbapenem breakpoints, which fail to detect carbapenem-resistant Enterobacteriaceae including MBL-producers 1. Isolates with imipenem MIC of 2 μg/mL have caused fatal infections despite appearing "susceptible" by outdated criteria.

Geographic and Epidemiologic Context

• Regional prevalence varies widely - MBL detection rates range from 0-2.6% across different facilities 7
• Rising global burden - MBL-producing Enterobacterales increased from 22.3% to 40% of carbapenemase-producers over recent years in some regions 8
• E. cloacae specifically - While less common than K. pneumoniae, E. cloacae MBL-producers are almost exclusively associated with MBL genes rather than other carbapenemase types 8

Treatment Implications

Once MBL production is confirmed or strongly suspected, avoid ceftazidime-avibactam monotherapy as it lacks MBL activity 2. The preferred regimen is aztreonam combined with ceftazidime-avibactam for severe infections 2, 9, 10.

The high mortality (18.8-41%) and morbidity associated with MBL-producing Enterobacteriaceae infections demands early recognition and appropriate targeted therapy 4, 10.